Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer
Authors
Keywords
-
Journal
Arthritis & Rheumatology
Volume 69, Issue 4, Pages 687-699
Publisher
Wiley
Online
2017-01-14
DOI
10.1002/art.40043
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology
- (2017) Laura C. Cappelli et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma
- (2016) N Matsumura et al. ACTA DERMATO-VENEREOLOGICA
- The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma
- (2016) B. Lee et al. ANNALS OF ONCOLOGY
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- (2016) A. M. Menzies et al. ANNALS OF ONCOLOGY
- Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
- (2016) Laura C Cappelli et al. ANNALS OF THE RHEUMATIC DISEASES
- Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases
- (2016) Leonard Calabrese et al. ANNALS OF THE RHEUMATIC DISEASES
- Coinhibitory Pathways in Immunotherapy for Cancer
- (2016) Susanne H. Baumeister et al. Annual Review of Immunology
- Managing Adverse Events With Immune Checkpoint Agents
- (2016) Ramona Dadu et al. CANCER JOURNAL
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
- (2016) Frank A. Schildberg et al. IMMUNITY
- Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non–Small Cell Lung Cancer (NSCLC)
- (2016) Puey Ling Chia et al. JOURNAL OF IMMUNOTHERAPY
- Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease
- (2016) Lara V. Maul et al. JOURNAL OF IMMUNOTHERAPY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
- (2016) Noha Abdel-Wahab et al. PLoS One
- A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors
- (2015) T. W. Chen et al. ANNALS OF ONCOLOGY
- Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells
- (2015) S. Kanameishi et al. ANNALS OF ONCOLOGY
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Strategies for combining immunotherapy with radiation for anticancer therapy
- (2015) Steven N Seyedin et al. Immunotherapy
- The association between CTLA-4 (+49 A/G) polymorphism and susceptibility to ankylosing spondylitis: a meta-analysis
- (2015) Jian Wu et al. International Journal of Rheumatic Diseases
- Toxicities of Immunotherapy for the Practitioner
- (2015) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab
- (2015) Tomohiko Narita et al. JOURNAL OF DERMATOLOGY
- Releasing the Brakes on Cancer Immunotherapy
- (2015) Antoni Ribas NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
- (2015) J Gao et al. ONCOGENE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Immune evasion in cancer: Mechanistic basis and therapeutic strategies
- (2015) Dass S. Vinay et al. SEMINARS IN CANCER BIOLOGY
- Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center
- (2015) Douglas B. Johnson et al. Cancer Immunology Research
- Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis
- (2015) A Doran Bostwick et al. Journal for ImmunoTherapy of Cancer
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
- (2015) Ahmad A. Tarhini et al. Journal for ImmunoTherapy of Cancer
- Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
- (2015) Heinz Läubli et al. Journal for ImmunoTherapy of Cancer
- TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study
- (2014) Pauline Raaschou et al. ANNALS OF THE RHEUMATIC DISEASES
- Th17 and regulatory T cell balance in autoimmune and inflammatory diseases
- (2014) Mélissa Noack et al. AUTOIMMUNITY REVIEWS
- Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease
- (2014) Magnus Pedersen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The effect of CTLA-4 A49G polymorphism on rheumatoid arthritis risk: a meta-analysis
- (2014) Gang Li et al. Diagnostic Pathology
- CTLA-4 polymorphisms and susceptibility to inflammatory bowel disease: A meta-analysis
- (2014) Young Ho Lee et al. HUMAN IMMUNOLOGY
- Kidney injuries related to ipilimumab
- (2014) Hassane Izzedine et al. INVESTIGATIONAL NEW DRUGS
- Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma
- (2014) Edward J Gettings et al. Multiple Sclerosis Journal
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- Meta-analysis of genetic polymorphisms in programmed cell death 1
- (2014) Y.H. Lee et al. ZEITSCHRIFT FUR RHEUMATOLOGIE
- In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
- (2014) C. Wang et al. Cancer Immunology Research
- Th17 Cells in Cancer: The Ultimate Identity Crisis
- (2014) Stefanie R. Bailey et al. Frontiers in Immunology
- Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
- (2014) Yi-chi M. Kong et al. Frontiers in Immunology
- Ipilimumab in patients with melanoma and autoimmune disease
- (2014) Chrisann Kyi et al. Journal for ImmunoTherapy of Cancer
- Immune Modulation in Cancer with Antibodies
- (2013) David B. Page et al. Annual Review of Medicine
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
- (2013) M. J. Selby et al. Cancer Immunology Research
- Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy
- (2012) Maria A. Lopez-Olivo et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer
- (2012) John Dulos et al. JOURNAL OF IMMUNOTHERAPY
- Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1
- (2012) Ester Simeone et al. Journal of Immunotoxicology
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents
- (2011) Pauline Raaschou et al. ARTHRITIS AND RHEUMATISM
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Hemophilia A Induced by Ipilimumab
- (2011) Julie Delyon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
- (2010) Le Min et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- PD-1 deficiency results in the development of fatal myocarditis in MRL mice
- (2010) Jian Wang et al. INTERNATIONAL IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
- (2010) Paolo A. Ascierto et al. SEMINARS IN ONCOLOGY
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Association between the PD1.3A/G polymorphism of thePDCD1gene and systemic lupus erythematosus in European populations: a meta-analysis
- (2009) J-L Liu et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
- (2009) Erika von Euw et al. Journal of Translational Medicine
- Anti-CTLA4 Antibody–Induced Lupus Nephritis
- (2009) Fouad Fadel et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- CTLA-4: a key regulatory point in the control of autoimmune disease
- (2008) Kenneth J. Scalapino et al. IMMUNOLOGICAL REVIEWS
- Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: a meta-analysis
- (2008) YH Lee et al. LUPUS
- T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR
- (2008) S. Sauer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started